A monoclonal antibody stands out against omicron subvariants: a call to action for a wider access to bebtelovimab - The Lancet

We read with great interest the Correspondence by Daichi Yamasoba and colleagues,1 which highlighted the efficacy of all commercially-available monoclonal antibodies against dominant omicron subvariants. In this Correspondence, similar to others,2 one monoclo…

We use cookies to help provide and enhance our service and tailor content and ads. To update your cookie settings, please visit the Cookie Preference Center for this site.Copyright © 2022 Elsevier In… [+173 chars]

full article...